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The distal convoluted tubule (DCT) plays an essential role in the
reabsorption of NaCl by the kidney, a process that can be inhibited
by thiazide diuretics. Parvalbumin (PV), a Ca2-binding protein that
plays a role in muscle ﬁbers and neurons, is selectively expressed
in the DCT, where its role remains unknown. We therefore inves-
tigated the renal phenotype of PV knockout mice (Pvalb/) vs.
wild-type (Pvalb/) littermates. PV colocalized with the thiazide-
sensitive Na-Cl cotransporter (NCC) in the early DCT. The
Pvalb/mice showed increased diuresis and kaliuresis at baseline
with higher aldosterone levels and lower lithium clearance. Acute
furosemide administration increased diuresis and natriuresis/kali-
uresis, but, surprisingly, did not increase calciuria in Pvalb/mice.
NaCl supplementation of Pvalb/ mice increased calciuria at
baseline and after furosemide. The Pvalb/ mice showed no
signiﬁcant diuretic response to hydrochlorothiazide, but an accen-
tuated hypocalciuria. A decreased expression of NCC was detected
in the early DCT of Pvalb/ kidneys in the absence of ultrastruc-
tural and apoptotic changes. The PV-deﬁcient mice had a positive
Ca2 balance and increased bone mineral density. Studies in
mouse DCT cells showed that endogenous NCC expression is
Ca2-dependent and can be modulated by the levels of PV expres-
sion. These results suggest that PV regulates the expression of NCC
by modulating intracellular Ca2 signaling in response to ATP in
DCT cells. They also provide insights into the Ca2-sparing action
of thiazides and the pathophysiology of distal tubulopathies.
distal convoluted tubule  kidney  salt-losing nephropathy 
sodium-chloride cotransport
Parvalbumin (PV) belongs to the superfamily of EF-hand Ca2-binding proteins that play a role in multiple cellular processes,
including gene transcription, ion transport, protein phosphoryla-
tion, and enzymatic activities (1). These proteins possess well
conserved helix–loop–helix motifs that bind Ca2 ions with high
affinity, leading to conformational changes. The conformational
plasticity and the cell-specific expression of these Ca2 sensor or
buffer proteins contribute to the versatility ofCa2 signaling (2). PV
is a 109-aa cytosolic protein that contains a pair of functional
EF-hand motifs forming a stable unit that binds two Ca2 ions (3).
This Ca2 buffer is expressed in a restricted number of vertebrate
tissues, including fast-contracting/relaxing skeletal muscle fibers
and GABA neurons in the brain (4). The generation of PV
knockout (Pvalb/) mice confirmed the important role played by
PV in muscle and brain (5). The fast muscles of Pvalb/ mice
exhibit a decreased relaxation rate of the twitch (5), suggesting that
PV facilitates Ca2 diffusion from myofibrils to the sarcoplasmic
reticulum (6). The lack of PV in the brain induces changes in
short-term synaptic plasticity and modified network properties,
resulting in increased susceptibility to epileptic seizures (7). Al-
though no human disease is associated with the PVALB gene on
22q12-q13.1, reduced GABA synthesis in PV-containing neurons
has been evidenced in individuals with schizophrenia and impaired
cognitive functions (8).
In addition to muscle fibers and neurons, PV is expressed in
epithelial cells lining the distal convoluted tubule (DCT) in rat and
mouse kidney (9, 10). The DCT reabsorbs5% of the filtered load
of Na, a process that involves the Na-Cl cotransporter (NCC)
and the ClC-Kb chloride channel, located on the apical and
basolateralmembrane of the cells, respectively. The reabsorption of
NaCl is inhibited by thiazide diuretics, which probably compete for
the Cl binding site of the apical NCC (11). The DCT also plays a
key role in the active Ca2 reabsorption in the distal nephron,
through a transcellular pathway that involves passive entry of Ca2
via the apical channel TRPV5, cytosolic diffusion to Ca2-binding
calbindins (CBs; CB-D28k and CB-D9k) and active basolateral
extrusion through Na-Ca2 exchanger 1 and plasma membrane
Ca2-ATPase 1b (PMCA1b) (12). Furthermore, the DCT is in-
volved in the final reabsorption of Mg2 through the apical channel
TRPM6 and a basolateral active transport (12). The selective
distribution of PV in the early part of the DCT, and its unique Ca2
buffering properties, raised the question of whether it may play a
role in the transport systems operating in that nephron segment.
In this study, we used Pvalb/ mice to investigate the effects of
PV on renal handling of NaCl and divalent cations in basal
conditions and after acute administration of diuretics and NaCl
repletion. The PV-deficient mice are characterized by a decreased
expression of NCC in the early DCT, leading to a discrete NaCl-
losing phenotype with impaired response to diuretics, and positive
Ca2 balance with increased bone mineral content and resistance.
The functional relationship between PV and NCC was further
studied in mouse DCT (mDCT) cells, revealing that PV modulates
the Ca2 transients induced by ATP and regulates the endogenous
expression of NCC.
Results
PV Is Distributed in the Early DCT of Mouse and Human. The cyto-
plasmic staining for PV was detected in a subset of tubules located
in the outer cortex of Pvalb/ kidneys (Fig. 1A). All PV-positive
segments showed apical NCC staining, thus confirming the distri-
bution of NCC in the DCT. However, PV is restricted to the early
part of the DCT, whereas NCC is expressed along the entire DCT,
and CB-D28k is more abundant in the distal part of the DCT and
Abbreviations: [Ca2]i, intracellular Ca2 concentration; CB, calbindin; DCT, distal convo-
luted tubule; mDCT, mouse DCT; GS, Gitelman’s syndrome; HCTZ, hydrochlorothiazide;
NCC, Na-Cl cotransporter; nNOS, neuronal nitric-oxide synthase; PMCA1b, plasmamem-
brane Ca2-ATPase 1b; PT, proximal tubule; PV, parvalbumin.
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the connecting tubule (Fig. 1B). The deletion of PV was not
reflected by structural and histological abnormalities in the kidney
[supporting information (SI) Fig. 6]. PV was also detected in the
human kidney (Fig. 1 C and D), located within the early DCT
identified by codistribution with uromodulin (Fig. 1E).
Pvalb/Mice Show Polyuria, Polydipsia, and Increased Kaliuresis. At
baseline, Pvalb/ mice exhibited increased kaliuresis, decreased
lithiumclearance, increased aldosteronuria, and a trend for reduced
calciuria, whereas magnesiuria and phosphaturia were unchanged
(Table 1). Body weight, hematocrit, renal function, acid/base status,
plasma osmolality, and electrolyte values were similar in both
genotypes. The Pvalb/ mice had a significant polyuria, with
diluted urine and higher fluid intake (Pvalb/: 8.0 1 vs.Pvalb/:
4.1  0.3 ml/24 h, n  6 pairs, P  0.002). Water deprivation
induced a similar antidiuresis (SI Fig. 7), ruling out a defective
urinary concentrating mechanism. The Pvalb/ mice had higher
plasma 1,25(OH)2D3 levels, with a trend for lower ionized Ca2
levels (Table 1).
Impaired Response to Furosemide and NaCl Supplementation in
Pvalb/ Mice. Furosemide was injected in Pvalb mice to increase
NaCl and Ca2 delivery to the DCT and test the role of PV in that
segment (Fig. 2). The anticipated diuretic response was observed in
both groups (Fig. 2A), paralleled by increased natriuria and kaliuria
(Fig. 2 B and C). Surprisingly, the furosemide-induced hypercalci-
uria, as observed inPvalb/mice,was absent inPvalb/mice (Fig.
2D). The Pvalb/ mice were then NaCl-repleted (Fig. 2 E and F)
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Fig. 1. Expression and distribution of PV in mouse and human kidney. (A) Double immunoﬂuorescence staining of mouse kidney cortex sections showing
immunopositive staining for PV and NCC and PV and CB-D28k. Note the different expression pattern of PV (cytosolic) and NCC (apical). (B) Distribution of
uromodulin (UMOD), PV, NCC, CB-D28k, and AQP2 along the nephron. TAL, thick ascending limb of Henle’s loop; DCT1, early part of the DCT; DCT2, late part
of DCT; CNT, connecting tubule; CCD, cortical collecting duct. (C) RT-PCR detection of PV in muscle and kidney samples from mouse and human (20 l of PCR
product per lane). (D) Immunoblotting of PV (11 kDa) in cytosolic extracts frommousemuscle and human kidney. (E) In human kidney, PV colocalizeswithUMOD
in the early DCT (*) following the TAL. (Scale bars: 100 m, A Upper Left; 20 m, A Upper Right; and 50 m, A Lower and E.)
Table 1. Biological parameters at baseline in Pvalb mice
Measurement Pvalb/ Pvalb/ P
Blood/plasma
Osmolality, mOsm/kg H2O 323  5 324  3 0.98
Hematocrit, % 46  1.7 43  1.4 0.27
Creatinine, mg/dl 0.25  0.02 0.28  0.02 0.26
Urea, mg/dl 24  2 27  2 0.22
Na, mM 141  1 142  0.4 0.42
K, mM 6.1  0.2 5.3  0.4 0.18
Mg², mM 2.5  0.2 2.8  0.2 0.32
tCO2, mM 24  1 22  0.4 0.16
Ionized Ca², mM 1.28  0.02 1.23  0.02 0.11
1,25(OH)2D3, pg/ ml 112  9 177  13* 0.001
Urine
Diuresis, l/ming body weight 0.03  0.01 0.05  0.01* 0.03
Osmolality, mOsm/kg H2O 3861  384 2610  226* 0.02
Na/creatinine, nmol/ng creatinine 0.36  0.03 0.35  0.03 0.85
K/creatinine, nmol/ng creatinine 0.35  0.01 0.43  0.03* 0.045
Ca2/creatinine, ng/ng creatinine 0.70  0.10 0.51  0.12 0.25
Mg2/creatinine, ng/ng creatinine 0.74  0.05 0.76  0.06 0.80
Fractional excretion, PO42 67  14 72  11 0.78
Lithium clearance, l/min 19.1  1.60 12.5  1.32* 0.01
Aldosterone, mol/min 6.5  1.6 18  9.9* 0.02
*, P  0.05 versus Pvalb/; n  6 pairs.
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to investigate whether the lower calciuria at baseline and the lack
of furosemide-induced hypercalciuria could reflect volume deple-
tion and compensatory NaCl and Ca2 reabsorption in the proxi-
mal tubule (PT), as suggested by the lower lithium clearance. The
Pvalb/ mice showed a striking avidity for the NaCl solution
(82% fluid intake, as comparedwith the usual tap water) that was
not observed inPvalb/mice (Fig. 2E). Short- and long-termNaCl
supplementation induced a significant increase in diuresis, natri-
uresis, calciuria, and magnesiuria in Pvalb/ mice (SI Table 2).
Administration of furosemide to the NaCl-repleted Pvalb/ mice
led to the anticipated increase of calciuria (195%; Fig. 2F), which,
however, remained lower than the values observed in Pvalb/
mice.
Impaired Response to Thiazide and Accentuated Hypocalciuria in
Pvalb/ Mice. A single dose of hydrochlorothiazide (HCTZ) was
injected to directly test theDCT (Fig. 3). ThePvalb/mice showed
the expected diuretic response, with natriuresis and a trend for
decreased calciuria (Fig. 3 A–D). Strikingly, the Pvalb/ mice
showed no diuretic response (Fig. 3A), contrasting with a significant
hypocalciuria (Fig. 3D). The time-dependent effect ofHCTZon the
urinary excretion of Na and Ca2 was investigated (Fig. 3 E and
F and SI Table 3). In Pvalb/ mice, Na excretion significantly
increased during the first 6 h after HCTZ, whereas calciuria was
unchanged. During the next 6 h, a significant decrease of natriuria
and calciuria was observed. In contrast, Pvalb/ mice already
showed a marked hypocalciuria during the first 6 h without signif-
icant natriuresis. The hypocalciuria was accentuated during the next
6 h, paralleled by a significant decrease of natriuria.
Taken together, the significant alterations observed in the
Pvalb/ mice at baseline and in response to loop and thiazide
diuretics hinted at a molecular defect in the DCT inducing several
tubular compensatory mechanisms.
The Deletion of PV Decreases the Expression of NCC in the DCT. To
investigate the potential mechanisms responsible for the phenotype
of Pvalb/ mice, we analyzed the renal expression of genes
involved in distal tubular transport (Fig. 4A). A 3-fold decrease in
the mRNA encoding NCC, paralleled by a 2-fold decrease in
WNK4 and the kidney-specific WNK1, was observed in Pvalb/
kidneys. In contrast, the mRNA levels of renin and neuronal
nitric-oxide synthase (nNOS) were up-regulated in Pvalb/ kid-
neys, whereas Na-K-ATPase, TRPV5, CB-D28k, PMCA1b,
Na-Ca2 exchanger 1, and ClC-Kb levels were unchanged. Im-
munoblotting confirmed the decreased expression of NCC in
Pvalb/ kidneys (Fig. 4B), with a weaker staining intensity and a
lower apical recruitment when compared with Pvalb/ mice (Fig.
4C). The few remaining profiles showing apical NCC staining were
strongly positive for CB-D28k, indicating that they belong to the
distal part of the DCT that does not express PV in vivo (data not
shown). Treatment with high-dose thiazide has been associated
with atrophy of the DCT epithelium and massive apoptotic cell
death (13). However, EM analysis did not show significant remod-
eling of the DCT cells in Pvalb/ mice, and negative TUNEL and
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Fig. 2. Furosemide testing and NaCl supplementation in Pvalb mice. (A–D)
Furosemide injection induces an increase in diuresis (A), natriuresis (B), and
kaliuresis (C), but no hypercalciuria (D) in the Pvalb/ mice. *, P  0.05 vs.
Pvalb/ baseline; †, P  0.05 vs. Pvalb/ baseline; ‡, P  0.05 vs. Pvalb/
furosemide. (E) Pvalb/ mice show a higher avidity for NaCl solution during
a48-h supplementation, comparedwithPvalb/mice receiving tapwater.No
such avidity is observed in Pvalb/mice. (F) Exposure of Pvalb/mice to oral
NaCl supplementation increases calciuria atbaselineand leads to theexpected
furosemide-induced hypercalciuria. *, P 0.05 vs. tap water (TW); †, P 0.05
vs. baseline (n  6 in each group).
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Fig. 3. Response to thiazide in Pvalb mice. (A–D) Diuresis (A), natriuresis (B),
kaliuresis (C), and calciuria (D) in six pairs of Pvalb mice at baseline and after
HCTZ is shown. The Pvalb/mice showno signiﬁcant diuretic response but an
accentuated hypocalciuria after HCTZ. *, P 0.05 vs. Pvalb/ baseline; †, P
0.05 vs. Pvalb/ baseline; ‡, P  0.05 vs. Pvalb/ furosemide. (E and F) Time
course ofNa (E) andCa2 (F) excretion 6 and12hafter a singleHCTZ injection
(n 9 pairs). In Pvalb/mice, Na excretion signiﬁcantly increases during the
ﬁrst 6 h, with unchanged calciuria. During the next 6 h, a signiﬁcant hypocal-
ciuriaoccurs, paralleledbyadecreasednatriuria. InPvalb/mice, a signiﬁcant
hypocalciuria is detected during the ﬁrst 6 h, without change in natriuria. The
hypocalciuria is accentuated during the next 6 h, paralleled by a decrease in
natriuria. †, P  0.05 vs. Pvalb/ baseline; *, P  0.05 vs. Pvalb/ baseline.
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poly(ADP-ribose)polymerase cleavage assays ruled out increased
apoptosis (SI Fig. 8).
Pvalb/ Mice Show Bone Modifications. Increased bone mineral
density is observed in association with thiazide treatment (14) and
in NCC-deficient mice and Gitelman’s syndrome (GS) patients
(15). We thus investigated whether the hypocalciuria and reduced
expression of NCC in Pvalb/ mice were likewise associated with
a bone phenotype. Detailed computed tomography analyses
showed a significant increase in the trabecular mineral content and
the periostal circumference and a higher mechanical resistance
(axial moment of inertia) in the proximal tibia of Pvalb/mice (SI
Fig. 9 and SI Table 4).
PV and Ca2 Signaling Regulate the Expression of NCC in mDCT Cells.
The mechanism by which PV could regulate NCC expression was
investigated in mDCT cells (16, 17), which endogenously express
PV and NCC (Fig. 5). We transfected the cells with various siRNA
against PV and showed that the knockdown of PV induces a
significant decrease in the expression of NCC (Fig. 5A). Inversely,
a strong and specific induction of NCC expression was observed in
different clones stably transfected with PV (Fig. 5B). Because DCT
cells are sensitive to P2 receptor-mediated purinergic signaling (18),
we tested whether PV could modulate ATP-induced Ca2 tran-
sients and NCC expression. Having confirmed the expression of
P2X and P2Y2 receptors by RT-PCR (data not shown), we showed
that 10 M ATP induces Ca2 transients in mDCT cells (Fig. 5C).
The transients were significantly reduced in cells stably transfected
with PV and cells exposed to the permeable Ca2 chelator EGTA-
AM. In parallel, we observed a 2-fold induction of NCC expression
in cells incubated with EGTA-AM, whereas stimulation with ATP
decreased the expression of NCC (Fig. 5D). The latter effect was
not observed in cells preincubated with EGTA-AM, demonstrating
the negative control that Ca2 transients exert on NCC expression.
The expression of PV and PMCA1b was unchanged in these
conditions.
Discussion
Our studies reveal that PV is critical for renal NaCl and Ca2
handling and the response to diuretics in mouse, by modulating the
Ca2 transients induced by ATP and regulating the endogenous
expression of NCC in DCT cells. These results are relevant when
considering the role of the DCT, the action of diuretics, and the
pathophysiology of distal tubulopathies.
Because the distribution of PV in kidney has been debated (10,
19), we confirmed that PV is restricted to the early DCT, where it
colocalizes with NCC. The deletion of PV entailed a discrete, but
consistent, phenotype. At baseline, Pvalb/ mice showed a poly-
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uria probably caused by polydipsia, because the urinary concen-
trating ability was unchanged. Their endogenous lithium clearance
was decreased, reflecting enhanced Na reabsorption in PT (20),
with higher aldosterone levels, increased kaliuria, and increased
expression of nNOS and renin, suggestive of volume depletion. The
Pvalb/ mice had similar body weight, hematocrit, and plasma
electrolyte levels compared with Pvalb/ mice, indicating that
compensatorymechanismswere efficient.Unexpectedly, treatment
of Pvalb/ mice with furosemide did not result in hypercalciuria,
indicating a dissociation of the natriuretic and calciuretic response.
Because hypovolemia triggers a compensatory PT reabsorption of
Na and Ca2, we conjectured that extracellular volume depletion
could play a role in the altered Ca2 handling in response to
furosemide. Indeed, NaCl-supplemented Pvalb/ mice increased
their baseline calciuria (which, however, remained lower than in
Pvalb/ mice; see Fig. 2) and showed the expected furosemide-
induced hypercalciuria. These data indicate a close relationship
between the extracellular volume status and the effect of loop
diuretics and a cross-talk between distal and proximal nephron
segments reflected in the tubular handling of Na and Ca2.
Analysis of Pvalb/ mice yielded information about the re-
sponse to thiazides. Administration of HCTZ to Pvalb/ mice
resulted in two remarkable features: a lack of diuretic response and
a significantly accentuated hypocalciuric effect. The impaired di-
uretic response probably reflects the decreased NCC expression in
the DCT (see Fig. 4) and compensatory reabsorption of Na in
both PT and collecting ducts (aldosterone-induced). The fact that
HCTZ induced a profound hypocalciuria without affecting natri-
uresis is particularly relevant. Studies in NCC-null mice (20) and
rats treated with high-dose HCTZ (21) demonstrated that en-
hanced PT-passive Ca2 transport contributes to thiazide-induced
hypocalciuria. The negative lithium clearance (and higher nNOS,
renin, and aldosterone levels suggestive of volume contraction)
indicates that the latter mechanism probably operates in Pvalb/
mice. However, our data suggest that an effect within the DCT is
also important. First, time-course analyses showed that, in Pvalb/
mice, HCTZ induces an early hypocalciuria without affecting
natriuresis. Second, when Pvalb/ mice are salt-repleted, their
urinary calcium/creatine ratio remains lower (0.75) than in wild-
type mice (1.3). These results indicate that thiazide-induced
hypocalciuria may occur without extracellular volume contraction,
consistent with a mouse model of chronic treatment with lower
doses of thiazide (22). Several models with enhanced PT-passive
Ca2 reabsorption are characterized by profound structural dam-
age of the DCT and/or a reduced expression of molecules involved
in the distal Ca2 transport (20, 21, 23). In contrast, the Pvalb/
mice have an intact DCT, which could be caused by the residual
expression of NCC, and the expression of molecules involved in
distal Ca2 transport is unchanged or even increased (CB-D9k)
(B.S., unpublished data). At any rate, PV is not required for Ca2
reabsorption: the coexistence of hypocalciuria with unchanged
plasma Ca2 levels indicated Ca2 accumulation in Pvalb/ mice
and bone mineral density was increased, as reported in NCC-
deficient mice and GS patients (15).
Although the salt-losing phenotype of the Pvalb/ mice bears
some resemblance with the NCC-deficient mice (23, 24), there are
differences between the strains. The Pvalb/ mice had polyuria
andpolydypsia at baseline, possibly related to increased kaliuria and
a trend toward hypokalemia. A central component may also
interfere, because PV is distributed in the brain and Pvalb/ mice
manifest a subtle locomotor phenotype (25). The NCC-null mice
had no disturbance of K homeostasis at baseline, but developed
inappropriate kaliuria, hypokalemia, polyuria, and polydypsia when
exposed to a low K diet (26). The Pvalb/ mice have no
hypomagnesemia without specific provocation, consistent with the
lack of structural changes in the DCT. In contrast, NCC knockout
mice show renal Mg2 wasting and hypomagnesemia at baseline,
likely caused by the severe damage in the DCT causing a loss in
TRPM6-expressing cells (23, 24). Genetic backgrounds, which are
important for the NCC-null phenotype (23, 24, 26), may also play
a role in differences between strains.
The lack of PV in the kidney was associated with a marked
down-regulation of NCC, with reduced apical targeting in most of
the DCT, in the absence of structural changes or apoptosis. The few
remaining tubule profiles showing apical NCC were strongly pos-
itive for CB-D28k, indicating their appartenance to the distal part
of the DCT that does not express PV in vivo. A reduced mRNA
level was also observed for WNK4 and the kidney-specific WNK1,
two serine/threonin kinases that interact to control NCC activity in
the DCT (27, 28). The decreased expression of both WNK4 and
WNK1 may thus constitute a compensatory mechanism (29) to
counteract the reduced expression of NCC in Pvalb/ mice.
The potential link between PV and NCC was investigated in
mDCT cells. The knockdown of PV by various siRNAs induced a
significant decrease in the expression of endogenous NCC, con-
firming the cellular specificity of the mechanism linking PV and
NCC. In neurons and skeletal muscle cells, PV acts as a cytosolic
Ca2 buffer that influences the shape and duration of Ca2
transients (30, 31). Such transients are physiologically involved in
the transcriptional regulation of several genes, including transport-
ers (32, 33). The distribution of PV in the early DCT, and the fact
that DCT cells are sensitive to purinergic signaling (18), led us to
show that ATP induced Ca2 transients in mDCT cells. This
ATP-induced Ca2 signal is modulated by PV and regulates the
endogenous expression of NCC. These results are consistent with
earlier studies showing that ATP increase intracellular Ca2 con-
centration ([Ca2]i) and inhibit Na absorption in the distal
nephron via luminal P2Y2 receptors (34). Further studies are
required to elucidate the link between modifications in the ampli-
tude and/or duration of Ca2 signals on downstream effectors such
as kinases and transcription factors in the DCT. Genes down-
regulated by Ca2 transients have been identified in Arabidopsis,
but the mechanisms have not been identified (35, 36).
On the basis of the evidence obtained in mouse and mDCT cells,
it is tempting to suggest that PV could play a role in human diseases
affecting the distal tubule. The phenotype of Pvalb/mice resem-
bles that observed in GS, an autosomal recessive tubulopathy
caused by inactivating mutations in the SLC12A3 gene coding for
NCC (37).GS is typically amild salt-losing disorder, associatedwith
secondary aldosteronism, hypocalciuria, and higher bone density
(38). More than 100 mutations in SLC12A3 have been identified,
although up to 40% of GS patients are found to carry only a single
mutation. The phenotype ofGS is highly heterogeneous, raising the
possibility of modifier genes (39). Thus, mutations or variants in
PVALB could be involved in SLC12A3-negative patients withGS or
resembling tubulopathies or participate in the phenotype variabil-
ity. Inherited or acquired variation in PV may also play a role in
NaCl handling in the DCT and the individual response to thiazides.
Methods
Animal Studies. Experiments were performed on age- and gender-
matched Pvalb littermates kept on a C57BL/6JSv129 background
(5, 6). Blood samples were obtained after anesthesia. The endog-
enous lithium clearance was used as an inverse measure of PT Na
reabsorption (20). Parameters were obtained at baseline and after
injection of furosemide or HCTZ (10 mg/kg, s.c.). The effect of
NaCl supplementation was investigated in Pvalb/ mice receiving
either tap water or 0.9% NaCl/0.1% KCl in drinking water for 48 h
or 2 weeks. All protocols complied with the National Research
Council Guide for the Care and Use of Laboratory Animals and
were approved by the local Ethics Committee.
Analytic Procedures. Plasma and urine parameters were measured
with a Synchron CX5 analyzer (Beckman Coulter, Fullerton, CA),
an i-STAT analyzer (Abbott Diagnostics, Ottignies, Belgium), an
osmometer (Fiske,NeedhamHeights,MA), or a flame photometer
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as appropriate. Plasma 1,25(OH)2 vitamin D3 (BARC, Ghent,
Belgium) and urine aldosterone (DPC, Humbeek, Belgium) were
measured by RIA.
RT-PCR and Real-Time Quantitative PCR. Samples were homogenized
in TRIzol. Total RNA was treated with DNase I and reverse-
transcribed by using SuperScript II Rnase H (Invitrogen, Carlsbad,
CA). The primers are listed on SI Table 5. RT-PCR detection was
performed with platinum TaqDNA polymerase (Invitrogen) for 32
cycles, and PCR products were visualized on a 1.5% agarose gel.
Real-time quantitative PCR analyses were performed in duplicate
by using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) (40).
PCR conditions were 94°C for 3 min followed by 40 cycles of 30 s
at 95°C, 30 s at 61°C, and 1 min at 72°C. The relative changes in
target gene/GAPDH mRNA ratio were determined by the for-
mula: 2		ct (40).
Antibodies. Antibodies against PV (Santa Cruz Biotechnology,
Santa Cruz, CA), NCC (a gift of D. H. Ellison, Oregon Health and
Science University, Portland, OR), AQP2 (Alomone, Jerusalem,
Israel), uromodulin (Biodesign International, Saco, ME), CB-D28k
(Swant, Bellinzona, Switzerland), and GFP (Westburg, Leusden,
Netherlands) were used.
Immunoblotting Analyses. Membrane and cytosol extraction and
immunoblotting were performed as described (40). The homoge-
nates were centrifuged at 1,000  g for 15 min at 4°C, and the
resulting supernatant was centrifuged at 100,000  g for 60 min at
4°C. Protein concentrations were determined with the bicincho-
ninic acid assay using BSA as standard.
Immunostaining. Kidney samples were fixed in 4% formaldehyde.
Six-micrometer paraffin sections were successively incubated in
0.3% H2O2, 10% normal serum, primary antibodies diluted in PBS
containing 2% BSA, biotinylated secondary antibodies, avidin-
biotin peroxidase, and aminoethylcarbazole or Texas red-
conjugated and FITC-conjugated avidin (Vector Laboratories,
Burlingame, CA). Sections were viewed under a DMR microscope
coupled to a DC300 digital camera (Leica, Heerbrugg,
Switzerland).
Bone Analysis. A high-resolution scanner (pQCT Research XCT-
SA; Norland-Stratec, Pforzheim, Germany) was used to analyze
the geometric and densitometry parameters of the tibia in anest-
ethized Pvalb mice (ref. 41 and SI Text).
Human Kidney Samples. Samples from human kidneys prepared for
transplantation were used for RNA and protein extraction and
immunohistochemistry as described. The use of these human
samples was approved by the local Ethical Review Board.
Cell Culture. The immortalized mDCT cells were kindly provided by
P. A. Friedman (University of Pittsburgh School of Medicine,
Pittsburgh, PA). The cells have been previously characterized as a
model for the thiazide-sensitive Na and Ca2 transport occurring
in the DCT (16, 17). The cells were grown in DMEM/Ham’s F-12
media (Lonza, Verviers, Belgium) supplemented with 5% FCS
(Lonza), 2 mM L-glutamine (Invitrogen), and a mixture of peni-
cillin/streptomycin in a humidified atmosphere of 95% air-5% CO2
at 37°C. Cell passages 20–35 were used. The knockdown of PV was
performed with 20 nM of double-stranded Silencer siRNA (Am-
bion, Lennik, Belgium) introduced into mDCT cells with Lipo-
fectamine 2000 (Invitrogen). RNA was extracted 48 h after trans-
fection. mDCT cells stably transfected with PV were obtained after
cloning the mouse PV sequence into a pAcGFP1-C In-Fusion
Ready Vector encoding a GFP (Westburg, Leusden, The Nether-
lands) and tranfection using FuGENE 6 Reagent (Roche, India-
napolis, IN). When appropriate, mDCT cells were treated with
EGTA-AM (10 M) for 6 h and after 4 h with(out) EGTA-AM,
cells were stimulated with ATP 10M for 6 min every hour for 6 h.
[Ca2]i Measurements. Cytosolic free Ca2 ([Ca2]i) concentration
was measured in individual mDCT cells using FURA2-AM as
described (ref. 42 and SI Text).
Data Analyses. Data are means  SEM. Statistical comparisons
were tested by two-tailed Student’s t test (Prism software; Graph-
Pad, San Diego, CA).
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